Risk stratification model to identify patients with high-risk smoldering multiple myeloma
In this MEDtalk Shaji Kumar, MD, Department of Hematology, Mayo Clinic Rochester, and the International Myeloma Working Group, suggests that a risk stratification model can be easily implemented i order to identify high-risk Smoldering multiple myeloma (SMM) to be used for clinical research and in routine practice. The study identifies a subgroup of SMM patients with 50% progression risk at 2 years from diagnosis.
